Prana Doses First Patient in the “IMAGINE” Phase II Alzheimer’s Disease Trial July 17, 2013August 16, 2022
Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson’s Disease January 28, 2022August 16, 2022
Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office December 29, 2022May 23, 2023